- You are here:
- Home »
- Blog »
- colon cancer »
- Stage 3 Colon Cancer Decision-making?
Stage 3 Colon Cancer Decision-making?
Stage 3 colon cancer decision-making can be overwhelming. My name is Bernie Davis. I was recently diagnosed with stage 3 colon cancer. I surgically removed the tumor but I haven’t had any other therapy yet. I’m researching what I can expect —what decisions I need to make.
Stage III Colon Cancer (Surgically Resected, No Adjuvant Therapy)
1. Baseline Prognosis
Stage III colon cancer means the tumor has spread to nearby lymph nodes but not to distant organs.
Surgery alone can remove all visible disease, but microscopic cancer cells often remain, which is why adjuvant chemotherapy is standard.
2. Evidence from Clinical Data
-
Without adjuvant chemotherapy, the recurrence risk is significantly higher.
-
Historical and modern data suggest 5-year overall survival (OS) after surgery alone is roughly:
-
Stage IIIA: ~60–70%
-
Stage IIIB: ~45–55%
-
Stage IIIC: ~30–40%
(Source: pooled analyses from SEER data, MOSAIC trial pre-chemo arms, and population registries)
-
By contrast, with standard adjuvant therapy (e.g., FOLFOX or CAPOX), 5-year OS improves by roughly 10–15 percentage points on average, depending on risk group.
3. Relapse and Cause of Death
-
Most recurrences occur within 2–3 years after surgery.
-
Common relapse sites: liver and lungs.
-
Local recurrence (in the colon or lymphatic bed) is less common but possible.
4. Other Prognostic Modifiers
-
Tumor biology: MSI-high (microsatellite instability–high) tumors have better outcomes and may benefit less from chemotherapy.
-
Number of lymph nodes positive: Fewer involved nodes → better prognosis.
-
Lymphovascular invasion, tumor grade, perineural invasion, and CEA level also influence relapse risk.
-
Patient health factors: age, comorbidities, fitness, and postoperative recovery matter substantially.
5. Quality of Life Considerations
Some patients decline chemotherapy because of toxicity risk, other health conditions, or personal preference. In these cases:
-
Intensive surveillance (CT scans, colonoscopy, and bloodwork every 3–6 months for 2–3 years) becomes essential.
-
Lifestyle interventions (diet, exercise, weight control, and avoiding smoking and excess alcohol) may modestly reduce recurrence risk.
-
Research suggests that plant-based diets, regular physical activity, and maintaining vitamin D sufficiency are associated with better long-term outcomes.
Summary Table
| Stage | 5-Year Overall Survival After Surgery Only | Typical With Chemo (FOLFOX/CAPOX) |
|---|---|---|
| IIIA | 60–70% | 75–85% |
| IIIB | 45–55% | 60–70% |
| IIIC | 30–40% | 45–55% |
The more I read about my risk of relapse, the more I think I should just bite the bullet and undergo adjuvant chemotherapy. But with diet, daily exercise and preparing my gut microbiome, I think 3 months of chemo rather than 6 months should reduce my risks of chemo side effects.
Have you undergone adjuvant chemo for stage 3 colon cancer? Scroll down the page, post a question or comment and I will reply to you ASAP.
thanks,
- Bernie Davis
- Colon Cancer Survivor
A new prognostic and predictive tool for shared decision making in stage III colon cancer
Highlights
- Survival of patients with stage III colon cancer varies according to T-N sub-stages.
- Average risk and benefit of adjuvant therapy is not applicable to individual patients
- We showed that T1N1a has 89% 5-year DFS and that T4N2b has 31% 5-year DFS.
- The contribution of each therapeutic option varied widely across sub-stages.
- The resulting overlay bar graph shows the absolute benefit of each treatment option.
Results
Large differences in 5-year DFS rate were observed among the subgroups, ranging from 89% (T1N1a) to 31% (T4N2b) in the overall population. The contribution to the outcome of each therapeutic option in this setting varied widely across sub-stages. According to our model, patients with T1N1a cancers have a projected 5-year DFS of 79.6% with surgery alone. Adjuvant fluoropyrimidine alone results in 5.6% absolute DFS gain; an additional 2.3% and 0.8% gain is seen with oxaliplatin for 3 and 6 months, respectively. Patients with T4N2b cancers show a 13.9% 5-year DFS with surgery alone, and an 11.2%, 6.4%, 2.5% increase with the aforementioned adjuvant options, respectively.
Conclusion
The resulting overlay bar graph gives patients and doctors the projected relative benefit of each treatment option and may substantially help the shared decision-making process, although caution must be exercised in using this model due to the significant variance of the estimates.
Stage 3 colon cancer decision-making Stage 3 colon cancer decision-making